Репозиторий
Публикация
Print
Публикация
Print

The cost of melanoma and kidney, prostate, and ovarian cancers in Russia

Автор
Игнатьева Виктория Игоревна
 
Соавторы
Авксентьева М.В., Омельяновский В.В., Деркач Е.В.
 
Тип публикации
Статья
 
Язык публикации
Русский
 
Аффилиация
РАНХиГС
 
Издательство
Value in Health Regional Issues: 4(1)
 
Год
2014
 
Количество страниц
58-65
 
Количество п.л.
8.00
 
Количество п.л. автора
5.00
 

Аннотация
Objective: The objective of this study was to assess the total annual economic burden of melanoma and kidney, prostate, and ovarian cancers in Russia using the unified methods. Methods: The general prevalence-based cost-of-illness model was developed to evaluate the annual health and social care costs and value of lost productivity attributable to the following cancers: melanoma and kidney, prostate, and ovarian cancers from the perspective of the overall governmental budget. All costs were calculated using the “bottom-up” costing technique for the total population of patients with studied cancer, including both newly diagnosed patients stratified by cancer stage and patients diagnosed in previous years who were still alive in the study year. Results: The lowest aggregate annual cost was found for melanoma—€17.48 million (52.4% health care costs, 34.9% social care costs, 12.7% attributed to productivity loss) and the highest—€84.52 million—for prostate cancer (72.0%, 19.0%, and 9.0%, respectively). Estimations for kidney and ovarian cancers were €45.33 and €45.56 million, respectively, with a similar distribution (42.5%–45.2% health care costs, 39.0%–40.3% social care costs, 14.5%–18.5% lost productiv- ity). Cost for a newly diagnosed patient was several times higher than for a patient diagnosed in previous years (€1144– €1947 vs. €145–€417, respectively). For patients in the first year after diagnosis, the major part of economic burden was attributed to health care costs, whereas for those diagnosed before the study year, costs not related to health were more prominent, except for prostate cancer. Conclusions: The economic impact of cancers is more prominent during the first year after diagnosis. A considerable part of the economic burden of cancer lies outside the health sector.

Ключевые слова
cancer, cost-of-illness, economic burden, health care costs

Контакты

СПРАВОЧНАЯ СЛУЖБА



Многоканальный телефон:
+7 499 956-99-99

E-mail:information@ranepa.ru
ПРИЕМНАЯ КОМИССИЯ
119571, г. Москва,
Проспект Вернадского, д. 84
Бакалавриат и специалитет:
Call-центр:
+7 499 956-99-99 (многоканальный)
Часы работы: 10.00 – 18.00

Магистратура:
Контакты приемных подкомиссий факультетов/институтов Академии
ПРЕСС-СЛУЖБА
119571, г. Москва,
Проспект Вернадского, д. 84, к. 2

Телефон:
+7 499 956-99-69



E-mail:press@ranepa.ru
Гостинично-жилой комплекс
119571, г. Москва,
Проспект Вернадского, д. 84, к. 2

Телефон:+7 499 956-00-44+7 495 434-33-25

E-mail: reserv@ranepa.ru

Президентская академия - лидирующий вуз России!